{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:15:22Z","timestamp":1761844522200},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1471-2407-14-983","type":"journal-article","created":{"date-parts":[[2015,6,18]],"date-time":"2015-06-18T07:05:12Z","timestamp":1434611112000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocol"],"prefix":"10.1186","volume":"14","author":[{"given":"Shibani","family":"Nicum","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corran","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucy","family":"Boyle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylwia","family":"Kopijasz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlie","family":"Gourley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcia","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Montes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Poole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Collins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Schuh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan J","family":"Dutton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,12,19]]},"reference":[{"issue":"5","key":"5154_CR1","doi-asserted-by":"publisher","first-page":"v181","DOI":"10.1093\/annonc\/mdj978","volume":"17","author":"RJ Ozol","year":"2006","unstructured":"Ozol RJ: Challenges for chemotherapy in ovarian cancer. Ann Oncol. 2006, 17 (5): v181-v187.","journal-title":"Ann Oncol"},{"key":"5154_CR2","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1093\/jnci\/92.7.564","volume":"92","author":"M Esteller","year":"2000","unstructured":"Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, Bussaglia E, Prat J, Harkes IC, Repasky EA, Gabrielson E, Schutte M, Baylin SB, Herman JG: Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst. 2000, 92: 564-569. 10.1093\/jnci\/92.7.564.","journal-title":"J Natl Cancer Inst"},{"key":"5154_CR3","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/1471-2407-6-212","volume":"6","author":"HJ Yang","year":"2006","unstructured":"Yang HJ, Liu VWS, Wang Y, Tsang PCK, Ngan HYS: Differential DNA methylationprofiles in gynaecological cancers and correlation with clinicopatholigical data. BMC Cancer. 2006, 6: 212-10.1186\/1471-2407-6-212.","journal-title":"BMC Cancer"},{"key":"5154_CR4","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nature03443","volume":"434","author":"HE Bryant","year":"2005","unstructured":"Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Menth M, Curtin NJ, Helleday T: Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase. Nature. 2005, 434: 913-917. 10.1038\/nature03443.","journal-title":"Nature"},{"issue":"7035","key":"5154_CR5","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer H, McCabe N, Lord CJ, Tutt ANJ, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NMB, Jackson SP, Smith GCM, Ashworth A: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005, 434 (7035): 917-921. 10.1038\/nature03445.","journal-title":"Nature"},{"key":"5154_CR6","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa0900212","volume":"361","author":"PC Fong","year":"2009","unstructured":"Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JHM, de Bono JS: Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers. N Engl J Med. 2009, 361: 123-134. 10.1056\/NEJMoa0900212.","journal-title":"N Engl J Med"},{"issue":"3","key":"5154_CR7","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1021\/bi00324a025","volume":"24","author":"AM Fichtinger-Schepman","year":"1985","unstructured":"Fichtinger-Schepman AM, van der Veer JL, den Hartog JH, Lohman PH, Reedijk J: Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation. Biochemistry. 1985, 24 (3): 707-713. 10.1021\/bi00324a025.","journal-title":"Biochemistry"},{"key":"5154_CR8","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1158\/0008-5472.CAN-08-0088","volume":"68","author":"EM Swisher","year":"2008","unstructured":"Swisher EM, Sakai W, Karlan BY, Wurz K, Urban N, Taniguchi T: Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. J Cancer Res. 2008, 68: 2581-2586. 10.1158\/0008-5472.CAN-08-0088.","journal-title":"J Cancer Res"},{"key":"5154_CR9","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1038\/nature06633","volume":"451","author":"W Sakai","year":"2008","unstructured":"Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C, Villegas E, Jacquemont C, Farrugia DJ, Couch FJ, Urban N, Taniguchi T: Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature. 2008, 451: 1116-1120. 10.1038\/nature06633.","journal-title":"Nature"},{"key":"5154_CR10","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1038\/nature06548","volume":"451","author":"SL Edwards","year":"2008","unstructured":"Edwards SL, Brough R, Lord CJ, Natrajan R, Vatcheva R, Levine DA, Boyd J, Reis-Filho JS, Ashworth A: Resistance to therapy caused by intragenic deletion in BRCA2. Nature. 2008, 451: 1111-1115. 10.1038\/nature06548.","journal-title":"Nature"},{"issue":"12","key":"5154_CR11","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1016\/0006-2952(88)90358-9","volume":"37","author":"JP B\u00f6kkerink","year":"1988","unstructured":"B\u00f6kkerink JP, Bakker MA, Hulscher TW, De Abreu RA, Schretlen ED: Purine de novo synthesis as the basis of synergism of methotrexate and 6-mercaptopurine in human malignant lymphoblasts of different lineages. Biochem Pharmacol. 1988, 37 (12): 2321-2327. 10.1016\/0006-2952(88)90358-9.","journal-title":"Biochem Pharmacol"},{"issue":"7","key":"5154_CR12","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1016\/0006-2952(93)90045-X","volume":"45","author":"JP B\u00f6kkerink","year":"1993","unstructured":"B\u00f6kkerink JP, Stet EH, De Abreu RA, Damen FJ, Hulscher TW, Bakker MA, van Baal JA: 6-Mercaptopurine: cytotoxicity and biochemical pharmacology in human malignant T- lymphoblasts. Biochem Pharmacol. 1993, 45 (7): 1455-1463. 10.1016\/0006-2952(93)90045-X.","journal-title":"Biochem Pharmacol"},{"issue":"6\u20137","key":"5154_CR13","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/emmm.200900040","volume":"1","author":"SA Martin","year":"2009","unstructured":"Martin SA, McCarthy A, Barber LJ, Burgess DJ, Parry S, Lord CJ, Ashworth A: Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2. EMBO Mol Med. 2009, 1 (6\u20137): 323-337.","journal-title":"EMBO Mol Med"},{"issue":"15","key":"5154_CR14","doi-asserted-by":"publisher","first-page":"6268","DOI":"10.1158\/0008-5472.CAN-09-3416","volume":"70","author":"N Issaeva","year":"2010","unstructured":"Issaeva N, Thomas HD, Djureinovic T, Jaspers JE, Stoimenov I, Kyle S, Pedley N, Gottipati P, Zur R, Sleeth K, Chatzakos V, Mulligan EA, Lundin C, Gubanova E, Kersbergen A, Harris AL, Sharma RA, Rottenberg S, Curtin NJ, Helleday T: 6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance. J Cancer Res. 2010, 70 (15): 6268-6276. 10.1158\/0008-5472.CAN-09-3416.","journal-title":"J Cancer Res"},{"issue":"4","key":"5154_CR15","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S0197-2456(01)00142-8","volume":"22","author":"SH Jung","year":"2001","unstructured":"Jung SH, Carey M, Kim KM: Graphical search for two-stage designs for phase II clinical trials. Control Clin Trials. 2001, 22 (4): 367-372. 10.1016\/S0197-2456(01)00142-8.","journal-title":"Control Clin Trials"},{"issue":"4","key":"5154_CR16","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/sim.1600","volume":"23","author":"SH Jung","year":"2004","unstructured":"Jung SH, Lee T, Kim K, George SL: Admissible two-stage designs for phase II cancer clinical trials. Stat Med. 2004, 23 (4): 561-569. 10.1002\/sim.1600.","journal-title":"Stat Med"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-14-983.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-14-983\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-14-983","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,7,12]],"date-time":"2016-07-12T21:47:46Z","timestamp":1468360066000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-14-983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["5154"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-14-983","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12]]},"article-number":"983"}}